

L Number	Hits	Search Text	DB	Time stamp
4	59	(ekwuribe-nnochiri\$ or price-christopher\$ or ansari-aslam\$ or odenbaugh\$).in.	USPAT; US-PGPUB	2004/01/31 13:07

Checked L4

JZ

1-31-2004

Day : Saturday  
Date: 1/31/2004

Time: 12:57:50

 **PALM INTRANET**

## Inventor Information for 09/873797

Inventor Name	City	State/Country
EKWURIBE, NNOCHIRI N.	CARY	NORTH CAROLINA
PRICE, CHRISTOPHER H.	CHAPEL HILL	NORTH CAROLINA
ANSARI, ASLAM M.	ROCKVILLE	MARYLAND
ODENBAUGH, AMY L.	MORRISVILLE	NORTH CAROLINA

[Appln Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity Data](#)[Foreign Data](#)Search Another: Application# or Patent# PCT /  /  or PG PUBS # Attorney Docket # Bar Code # 

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Checked  
Jen  
1-31-2004

L Number	Hits	Search Text	DB	Time stamp
9	93	(conjugat\$ same ((peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$))) and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:41
10	223	(conjugat\$ or peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and (514/2,11,12,21; 530/345,410; 528/425; 554/227; 562/587; 568/613,618,622,623).ccls. and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:15
11	204	((conjugat\$ or peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and (514/2,11,12,21; 530/345,410; 528/425; 554/227; 562/587; 568/613,618,622,623).ccls. and @pd>20030204) not ((conjugat\$ same ((peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$))) and @pd>20030204)	USPAT; US-PGPUB	2004/01/31 15:20
12	1	2000wo-jp09159.ap.	USPAT; US-PGPUB; DERWENT	2004/01/31 15:30
13	187	(polypropyleneglycol or polypropylene adj glycol or polyoxypropylene\$ or oxypropylene\$) same (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:42
14	36	(polypropyleneglycol or polypropylene adj glycol or polyoxypropylene\$ or oxypropylene\$) with (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:35
15	42	(polyalkyleneglycol or polyalkylene adj glycol or polyoxyalkylene\$ or oxyalkylene\$) with (uniform\$ or homogenous or homogeneous or monodispers\$ or polydispers\$) and @pd>20030204	USPAT; US-PGPUB	2004/01/31 15:42
16	1053	(424/193.1-197.11).ccls.	USPAT; US-PGPUB	2004/01/31 15:41
17	3991	conjugat\$ with (peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$ or polypropyleneglycol or polypropylene adj glycol or polyoxypropylene\$ or oxypropylene\$ or polyalkyleneglycol or polyalkylene adj glycol or polyoxyalkylene\$ or oxyalkylene\$)	USPAT; US-PGPUB USPAT; US-PGPUB	2004/01/31 15:43
18	62	((424/193.1-197.11).ccls.) and (conjugat\$ with (peg or pegylat\$ or polyethyleneglycol or polyethylene adj glycol or polyoxyethylene\$ or oxyethylene\$ or polypropyleneglycol or polypropylene adj glycol or polyoxypropylene\$ or oxypropylene\$ or polyalkyleneglycol or polyalkylene adj glycol or polyoxyalkylene\$ or oxyalkylene\$))	USPAT; US-PGPUB	2004/01/31 15:43

Checked L9, L10, L11, L14, L15, L18  
JSL 1-31-2004

DERWENT-ACC-NO: 1992-367710

DERWENT-WEEK: 199911

COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: Hypocalcaemic calcitonin conjugates  
- comprise carboxylic acid gp. bonded to polymer  
having polyethylene glycol derivs.

INVENTOR: BAUDRIHAYE, M; DE CLERCQ, P ; MATHIEU, F ;  
WANTIER, H

PATENT-ASSIGNEE: TEVA PHARM IND LTD[TEVAN] , MEDGENIX  
GROUP SA[MEDGN]

PRIORITY-DATA: 1991FR-0004990 (April 23, 1991)

PATENT-FAMILY:

PUB-NO	PAGES	PUB-DATE	
LANGUAGE		MAIN-IPC	
EP 511903 A2		November 4, 1992	F
009	C08G	065/32	
ES 2124247 T3		February 1, 1999	N/A
000	C08G	065/32	
FR 2675807 A1		October 30, 1992	N/A
020	C08G	065/32	
EP 511903 A3		August 11, 1993	N/A
000	C08G	065/32	
EP 511903 B1		October 14, 1998	F
000	C08G	065/32	
DE 69227276 E		November 19, 1998	N/A
000	C08G	065/32	

DESIGNATED-STATES: AT BE CH DE DK ES FR GB GR IT LI LU MC  
NL PT SE AT BE CH DE  
DK ES FR GB GR IT LI LU MC NL PT SE

CITED-DOCUMENTS: No-SR.Pub; 1.Jnl.Ref ; EP 400472 ; EP  
400486 ; JP 61178926  
; US 4179337

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-DESCRIPTOR	APPL-NO
EP 511903A2		N/A	
1992EP-0401164		April 23, 1992	
ES 2124247T3		N/A	
1992EP-0401164		April 23, 1992	
ES 2124247T3		Based on	EP 511903
N/A			
FR 2675807A1		N/A	
1991FR-0004990		April 23, 1991	
EP 511903B1		N/A	
1992EP-0401164		April 23, 1992	
DE 69227276E		N/A	
1992DE-0627276		April 23, 1992	
DE 69227276E		N/A	
1992EP-0401164		April 23, 1992	
DE 69227276E		Based on	EP 511903
N/A			

INT-CL (IPC): A61K047/48, C07K007/36 , C07K017/08 ,  
C08G065/32

ABSTRACTED-PUB-NO: EP 511903A

#### BASIC-ABSTRACT:

Calcitonin conjugates (I) comprise a calcitonin (II) covalently bonded via at least one COOH gp. to at least one polymer (III) having a polyethylene glycol (PEG) chain.

USE/ADVANTAGE - Used in the treatment of osteoporosis, hypercalcaemia, Paget's disease, acute pancreatitis and sudeckatrophy. (I) have a longer plasma half-life, are less immunogenic, have almost the same receptor binding affinity, and have comparable hypocalcaemic activity in vivo. Pref. (III) is a PEG deriv. of formula  $\text{Me}(\text{OCH}_2\text{CH}_2)_n\text{NH}_2$ , where N is molecular wt. of 500-20,000, esp. 400-10,000. (III) is human, salmon or eel calcitonin or a calcitonin analogue with Asp or Glu in posn. 15. (II) is coupled to (III) through a peptide bond linking the COOH gp. in position 15

with the NH<sub>2</sub> gp. in  
(II).

ABSTRACTED-PUB-NO: EP 511903B

EQUIVALENT-ABSTRACTS:

Calcitonin conjugates (I) comprise a calcitonin (II) covalently bonded via at least one COOH gp. to at least one polymer (III) having a polyethylene glycol (PEG) chain.

USE/ADVANTAGE - Used in the treatment of osteoporosis, hypercalcaemia, Paget's disease, acute pancreatitis and sudeckatrophy. (I) have a longer plasma half-life, are less immunogenic, have almost the same receptor binding affinity, and have comparable hypocalcaemic activity in vivo. Pref. (III) is a PEG deriv. of formula Me(OCH<sub>2</sub>CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, where N is molecular wt. of 500-20,000, esp. 400-10,000. (III) is human, salmon or eel calcitonin or a calcitonin analogue with Asp or Glu in posn. 15. (II) is coupled to (III) through a peptide bond linking the COOH gp. in position 15 with the NH<sub>2</sub> gp. in (II).

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: HYPOCALCAEMIC CALCITONIN CONJUGATE COMPRISE  
CARBOXYLIC ACID GROUP  
BOND POLYMER POLYETHYLENE GLYCOL DERIVATIVE

DERWENT-CLASS: A96 B04

CPI-CODES: A10-E07; A12-V01; B04-B02D3; B04-C03C; B12-G01;  
B12-G03; B12-G07;  
B12-J08;

CHEMICAL-CODES:

Chemical Indexing M1 \*01\*

Fragmentation Code

D011 D601 F012 F014 F423 F521 G010 G013 G100 H1  
H100 H101 H181 H182 H4 H401 H402 H441 H481 H482

